GO
Loading...

Drug Retail

More

  • Marijuana: Doobie Do's and Don'ts     Friday, 7 Dec 2012 | 2:50 PM ET

    CNBC's Jane Wells reports Washington's new state law that makes it legal to smoke pot, is more complicated than it sounds, and Allen St. Pierre, NORML executive director, weighs in on the financial benefits of reforming marijuana laws.

  • Some 150 workers at TriHealth, a Cincinnati-based health care company are unemployed today because they refused to get a free, company-sponsored flu shot. Michael Cannon, Cato Institute, thinks the company has a right to make this decision, while Barbara Fisher, National Vaccine Information Center, thinks this a violation of the workers' informed consent rights.

  • Liberals' Pipe Dream: A Nation of Stoners?     Thursday, 8 Nov 2012 | 7:52 PM ET

    Colorado and Washington made history on Tuesday becoming the first states to legalize the recreational use of marijuana. Janine Turner, Constituting America founder & co-chair, says "this is really disappointing, and stealing the promise of the future of America."

  • Can Statins Reduce Cancer Deaths?     Thursday, 8 Nov 2012 | 7:45 PM ET

    A new study out today in The New England Journal of Medicine finds statin use reduces the risk of death from cancer. Dr. Lori Mosca of New York Presbyterian Hospital and Columbia University Medical Center, offers insight on the drug and its side effects.

  • Marijuana Use Remains Against Federal Law     Thursday, 8 Nov 2012 | 2:45 PM ET

    The marijuana business is worth more than $300 billion worldwide, with CNBC's Brian Shactman & Brian Vicente, Campaign to Regulate Marijuana Like Alcohol.

  • NPS Pharmaceuticals CEO on Orphan Drugs     Wednesday, 24 Oct 2012 | 6:45 PM ET

    NPS Pharmaceuticals president & CEO Dr. Francois Nader, discusses strategies his company uses to finding value for shareholders, and appealing to the FDA.

  • Healthy Vitamin Stocks     Wednesday, 17 Oct 2012 | 2:37 PM ET

    Why vitamin stocks are moving higher, with CNBC's Seema Mody.

  • Deadly Meningitis Threat     Monday, 8 Oct 2012 | 7:22 PM ET

    NBC's Tom Costello reports on the outbreak of meningitis tied to a contaminated drug, saying as many as 13,000 people may have received one of the contaminated steroids.

  • Why Investors Like Pharma Stocks     Monday, 8 Oct 2012 | 2:23 PM ET

    Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.

  • New Alzheimer's Data Shows Promise     Monday, 8 Oct 2012 | 1:16 PM ET

    Medical experts convening at the American Neurology Association meeting to evaluate phase 3 Alzheimer's data on a drug from Eli Lilly. CNBC's Seema Mody reports.

  • Lance Armstrong: Enough Is Enough     Friday, 24 Aug 2012 | 7:24 PM ET

    Lance Armstrong has announced he will no longer fight accusations that he used performance enhancing substances during his cycling career, with CNBC's Erin Sharoni.

  • The Economics of Pot Legalization     Thursday, 23 Aug 2012 | 4:39 PM ET

    One argument made in defense of legalizing pot is an economic one: a boost in revenue from taxes, lower cost in fighting the war on drugs, and even a solution to the nation's energy problem. Kevin Sabet, former White House Advisor on drug policy, and freelance journalist Doug Fine, discuss the war on drugs in the U.S. and the economics involved.

  • The Politics of Pot     Thursday, 23 Aug 2012 | 4:37 PM ET

    Could President Obama lose Colorado if he does not fix issues facing pot-related businesses? CNBC's Brian Shactman reports.

  • Banking on Pot     Thursday, 23 Aug 2012 | 2:25 PM ET

    Wells Fargo tells CNBC they have "opted not to bank" with pot businesses because "while medical marijuana dispensaries are legal in some states, they are still illegal under federal law," reports CNBC's Brian Shactman.

  • Politics & Pot     Thursday, 23 Aug 2012 | 1:46 PM ET

    If Amendment 64, which legalizes Marijuana and regulates it like alcohol, passes in Colorado this November, the state could see $64 million more in taxes, reports CNBC's Brian Shactman.

  • Uproar Over Peter Thiel's Facebook Sale     Wednesday, 22 Aug 2012 | 1:50 PM ET

    Should Peter Thiel be allowed to stay on Facebook's board since selling his shares. Is the criticism of Nike's $300 shoe fair? And the Candy Lady is making candy that looks like crystal meth, with CNBC's John Carney & Julia Boorstin.

  • Johnson & Johnson's Challenges     Monday, 20 Aug 2012 | 2:50 PM ET

    Johnson & Johnson has faced multiple product recalls over the years, with CNBC's Seema Mody. Tony Butler, Barclays, offers insight.

  • Closing Drug 'Doughnut Hole' Saves $687 Million in 2012 Wednesday, 25 Jul 2012 | 2:39 PM ET

    A provision of the Affordable Care Act squeezes premiums that drugmakers collect from the government has yielded savings of $687 million in the first six months of 2012.

  • Warning: Synthetic Drugs     Friday, 20 Jul 2012 | 12:00 AM ET

    Chief William T. Riley, Selma Police Department, discusses the successful raid of a Selma, Alabama gas station where synthetic drugs were confiscated and explains how police warned local stores about the new breed of drugs.

  • Crime Inc: Synthetic Drugs     Friday, 20 Jul 2012 | 12:00 AM ET

    On February 1, 2012, the Selma Police department in Alabama raided a local gas station and confiscated more than $15,000 worth of a new grade of synthetic marijuana called the Blue Bomb. Detective Kendall Thomas describes what was found.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.